Lippincott, Williams & Wilkins, Pharmacogenetics and Genomics, 12(21), p. 861-866, 2011
DOI: 10.1097/fpc.0b013e32834c6edb
Full text: Download
CYP3A4 is involved in the oxidative metabolism of many drugs and xenobiotics including the HMG-CoA reductase inhibitor simvastatin. The objective of this study was to investigate whether a new CYP3A4 functional single nucleotide polymorphism (SNP) in intron 6 (CYP3A4*22) modifies the effect of simvastatin on total cholesterol (TOTc) or LDL cholesterol (LDLc) reduction in a population-based cohort study.